Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21332462 | 0.86 | KMT2A (0.66) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL30238049 | 0.85 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL1800381 | 0.85 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL1020573 | 0.84 | KMT2A (0.61) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31173373 | 0.83 | KMT2A (0.62) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31031957 | 0.83 | KMT2A (0.67) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL401725 | 0.83 | KMT2A (0.67) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL411680 | 0.83 | KMT2A (0.62) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29728458 | 0.83 | KMT2A (0.62) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL12866016 | 0.83 | KMT2A (0.62) | KMT2AEPHX2FABP5FABP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| EP-1301527-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2003-04-16 | — | — | EP | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | claimed |
| WO-2002008251-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| CN-106589111-B | Synthetic method of bremer langdan | 江苏开元医药化工有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-101142228-A | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity | POLYPHOR LTD (CH) | 2008-03-12 | — | — | CN | disclosed |
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003068807-A2 | ECHINOCANDIN CYCLIC PEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-08-21 | — | — | WO | disclosed |
| EP-1330550-A2 | ATROPISOMERS OF ASYMMETRIC XANTHENE FLUORESCENT DYES AND METHODS OF DNA SEQUENCING AND FRAGMENT ANALYSIS | Applera Corporation (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-1301527-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002036832-A2 | ATROPISOMERS OF ASYMMETRIC XANTHENE FLUORESCENT DYES AND METHODS OF DNA SEQUENCING AND FRAGMENT ANALYSIS | APPLERA CORPORATION (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002008251-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, TMPRSS15, TMPRSS11D | KMT2A 3141/4885EPHX2 3195/4885FABP5 1652/4885 |
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | NGLY1, ARG1, ERG28 | KMT2A 4485/4885EPHX2 3256/4885FABP5 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.